Oslo, Norway, December 22, 2021 - An Extraordinary General Meeting of Nykode
Therapeutics AS was held on December 22, 2021. All proposed resolutions on the
agenda were approved in accordance with the notice for the meeting published on
December 15, 2021.
Minutes of the meeting are attached hereto.
About Nykode Therapeutics
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment cancer and infectious diseases. Nykode Therapeutics' modular vaccine
technology specifically targets antigens to Antigen Presenting Cells, which are
essential for inducing rapid, strong and long-lasting antigen specific immune
responses and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment
of human papilloma virus 16 induced malignancies which is in Phase 2 for the
treatment of cervical cancer